Beijing Konruns Pharmaceutical Co., Ltd. Class ASSE: 603590

Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

· Issued by Beijing Konruns Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis